Trial Profile

A Phase I Dose Escalation Study Evaluating MK-8109 (Vintafolide) in Japanese Subjects With Advanced Solid Tumor

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 09 Jun 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vintafolide (Primary)
Indications Solid tumours
Focus Adverse reactions
Sponsors Merck Sharp & Dohme

Most Recent Events

14 Jul 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
11 Mar 2014 Planned End Date changed from 1 Jun 2015 to 1 Mar 2015 as reported by ClinicalTrial.gov record.
11 Mar 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrial.gov record.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com